NCT04452162 Physiologic MR Imaging of Salivary Gland Tumors
| NCT ID | NCT04452162 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Salivary Gland Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2020-08-25 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2020-08-25 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.
Eligibility Criteria
Inclusion Criteria: * Possess a salivary gland lesion of 1cm3 size * Have no prior history of treatment for salivary gland lesion Exclusion Criteria: * Has any prior history of cancer other than SGT * Has any MRI contra-indications * Has a history of known renal disease. * Has history of prior radiation to head and neck region * Is pregnant
Contact & Investigator
Sanjeev Chawla
PRINCIPAL INVESTIGATOR
Professor
Frequently Asked Questions
Who can join the NCT04452162 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Salivary Gland Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04452162 currently recruiting?
Yes, NCT04452162 is actively recruiting participants. Contact the research team at Marisa.Sanchez@pennmedicine.upenn.edu for enrollment information.
Where is the NCT04452162 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT04452162 clinical trial?
NCT04452162 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Sanjeev Chawla at Professor. The trial plans to enroll 30 participants.